Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
87 participants
OBSERVATIONAL
2011-12-31
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Drug utilization of Microbial Collagenase in the hand of physicians, with focus on feasibility, treatment patterns, and effectiveness in clinical practice
* Context of Microbial Collagenase therapy (setting, patient characteristics, concomitant treatment, follow-up therapy)
* Effectiveness (with focus on functionality)
* Tolerability
* Patient-related outcomes: patient satisfaction, health-related quality of life
* Physician satisfaction with therapy
* Resource utilization (hospital stays, drug consumption, concomitant medication etc.)
* Long-term outcomes
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* satisfactory knowledge of German to be able to fill out questionnaires
* written informed consent
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GWT-TUD GmbH
OTHER
Pfizer
INDUSTRY
Technische Universität Dresden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Pittrow, MD, PhD
Role: STUDY_DIRECTOR
Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden, Germany
Wilhelm Kirch, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Institute for Clinical Pharmacology (Director), Medical Faculty, Technical University, Dresden, Germany
Max Härle, MD
Role: STUDY_DIRECTOR
Orthopädische Klinik, Markgröningen, Germany
Jörg Witthaut, MD
Role: STUDY_DIRECTOR
Schön Klinik Vogtareuth
Riccardo Giunta, MD
Role: STUDY_DIRECTOR
Hand Surgery, Ludwig-Maximilian-University Munich, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prof. Dr. Max Haerle
Markgröningen, , Germany
Prof. Dr. Riccardo Giunta
Munich, , Germany
Several undisclosed sites
Various Cities, , Germany
Dr. Joerg Witthaut
Vogtareuth, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Publication of results in the German Mecial Science (GMS) database
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ReDuCTO ID 7090
Identifier Type: -
Identifier Source: org_study_id